Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions
상품코드:1688869
리서치사:BCC Research
발행일:2025년 03월
페이지 정보:영문 211 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 재발 및 전이 부문을 중심으로 한 암 치료제 시장 규모는 2024년 1,161억 달러로 평가되었습니다. 예측 기간 중에는 7.7%의 연평균 복합 성장률(CAGR)로 성장할 전망이고 2029년 말에는 1,680억 달러에 달할 것으로 예상되고 있습니다.
폐암 치료제 부문은 2024년 162억 달러로 평가되었습니다. 12.4%의 연평균 복합 성장률(CAGR)로 성장할 것으로 전망되고 2029년에는 290억 달러에 이를 것으로 예측됩니다. 로 예측됩니다. 유방암 치료제 부문은 2024년 137억 달러에 이르렀습니다. CAGR 11.4%로 성장할 것으로 예상되며 2029년에는 236억 달러에 이를 것으로 예측됩니다.
본 보고서에서는 세계의 재발 및 전이 부문을 중심으로 한 암 치료제 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 법규제 환경, 신기술 및 기술 개발 동향, 시장 규모 추이와 예측, 각종 구분, 지역별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.
목차
제1장 주요 요약
시장 전망
조사 범위
시장 요약
제2장 시장 개요
개요
전이성 또는 재발성 암 치료의 유형
수술
화학 치료
방사선 치료
표적 치료
암 면역 치료
종양 용해성 바이러스 치료
항체 약물 복합체
Porter's Five Forces 분석
제3장 시장 역학
시장 역학
시장 성장 촉진요인
항암제의 강력한 승인
암 치료에 있어서의 기술의 진보
암 발병률 증가
시장 성장 억제요인
독점성의 상실과 일반화
종양 전문가의 부족
시장 기회
종양 부문에서 AI 도입
파이프라인 후기 단계에 있는 유망한 의약품
제4장 규제 상황
미국 승인 프로세스
암 치료제 개발에 관한 FDA 규제 고려 사항
EU 승인 프로세스
EU 승인 프로세스의 현상
일본 승인 프로세스
제5장 새로운 동향과 파이프라인 분석
신흥기술
개인화된 암 백신
18유형의 조기암을 식별하는 검사
CAR T 세포 치료
AI
유방암 위험을 줄이는 태블릿
나노입자
가압 복강 내 에어로졸 화학 치료
자궁경부암 치료의 획기적인 진보
새로운 전개
바이오시밀러의 승인
파이프라인 분석
임상시험 분석
특허 분석
중요 포인트
제6장 공급망 분석
개요
연구개발
제조
포장
도매 유통업체 및 재포장업체
약국
소비자 유통
항암제 부족
비용
제조의 복잡성
지리적 집중도
품질
제7장 시장 세분화 분석
세분화의 내역
시장 분석 : 암 유형별
폐암
유방암
대장암
전립선암
위암
간암
자궁경부암
방광암
신장암
췌장암
난소암
기타
지리적 내역
시장 분석 : 지역별
북미
유럽
아시아태평양
기타 지역
제8장 경쟁 정보
개요
블록버스터 종양 치료제 브랜드
주요 기업의 시장 점유율
제9장 재발 및 전이 부문을 중심으로 한 암 치료제 시장 : 지속가능성과 ESG 관점
제약 업계에서 ESG의 역할
ESG 성능 분석
환경 요인
사회적 요인
거버넌스 요인
ESG 위험 평가
총론
제10장 부록
조사 방법
신흥 스타트업 기업/시장 파괴자
출처
약어
기업 프로파일
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BAYER AG
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
KTH
영문 목차
영문목차
The global market for cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $116.1 billion in 2024 to reach $168.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2029.
The global market for lung cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $16.2 billion in 2024 to reach $29.0 billion by 2029, at a CAGR of 12.4% from 2024 to 2029.
The global market for breast cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $13.7 billion in 2024 to reach $23.6 billion by 2029, at a CAGR of 11.4% from 2024 to 2029.
Report Scope
Both qualitative and quantitative data on the current dynamics impacting the global cancer therapeutics market are presented in this report. It discusses the history of cancer, its different forms, its pathophysiology, its stages of development and its mechanisms of metastasis and recurrence. It also incorporates the disease burden by knowing the epidemiology of different cancers. Treatment patterns that include both non-pharmacological (e.g., radiation, surgery) and pharmacological (e.g., hormonal therapy, targeted therapy, cytotoxic/chemotherapy, combinatorial therapy) approaches are discussed to illustrate the various therapeutic options available to patients.
Analyses of the most popular products, the state of clinical trials and new product approvals are also included in the report. The demographics of the major regions-North America, Europe, Asia-Pacific and the Rest of the World-as well as their prospects for growth, are summarized. The profiles of leading companies and the strategies of international businesses involved in the cancer treatment sector are also discussed.
Estimations of the market size for therapies that treat cancer metastases and recurrence states are included in the scope. Cancer types noted in this report include:
Lung.
Breast.
Liver.
Stomach.
Prostate.
Colorectal.
Gastric.
Cervical.
Bladder.
Kidney.
Ovarian.
Lymphoma.
Multiple myeloma.
Brain tumors.
Thyroid.
Uterine.
Additional growth potential and forecast data are discussed for the cancer therapeutics market, as well as for the cancer types, regions and countries.
For market estimates, data are provided for 2023 as the base year, with forecasts for the period of 2024 through 2029.
Report Includes
51 data tables and 83 additional tables
An overview of the global market for cancer therapeutics with emphasis on recurrent and metastatic divisions
Analyses of global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by cancer type and region
A look at the factors driving the market's growth and constraints
Insight into the industry value chain analysis, providing a study of the intermediaries involved
Description of cancer development stages, including the mechanisms of metastasis and recurrences, and the current diagnostics such as medical imaging, in vitro diagnostics technologies and treatment patterns
Coverage of causes, risk factors, prevalence and incidence of cancer, and information on its economic burden
Review of pharmacological approaches covering cytotoxic/chemotherapy, hormonal therapy, targeted therapy and combinatorial therapy and non-pharmacological treatments such as surgeries and radiation
Identification of the fastest-growing applications and technologies, and a review of current market trends
Discussion of the industry's ESG challenges and practices
Review of the current market status, technology issues, industry value chain, Porter's Five Forces, competitive landscape, R&D activity and patent analysis
Assessment of the vendor landscape, including the market shares of leading companies, their product portfolios and financial overviews
Updates on recent mergers and acquisitions, facility expansions, collaborations, investments, divestments, new products and other strategic developments
Profiles of the leading vendors, including Merck & Co. Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., and AstraZeneca
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Metastatic or Recurrent Cancer Treatment Types
Surgery
Chemotherapy
Radiotherapy
Targeted Therapy
Cancer Immunotherapies
Oncolytic Virotherapy
Antibody-Drug Conjugates
Porter's Five Forces Analysis in the Oncology Market
Potential of New Entrants
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of Substitute Products or Services
Industry Rivalry: High
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Robust Approval of Oncology Drugs
Technological Advances in Cancer Treatments
Increasing Incidence of Cancer Disease
Market Restraints
Loss of Exclusivity and Genericization
Lack of Oncology Professionals
Market Opportunities
Incorporation of Artificial Intelligence in Oncology
Promising Drugs in the Late Stage of the Pipeline
Chapter 4 Regulatory Landscape
The U.S. Approval Process
FDA Regulatory Considerations for Oncology Drug Development
European Union Approval Process
Current Situation in E.U. Approval Process
Japanese Approval Process
Chapter 5 Emerging Trends and Pipeline Analysis
Emerging Technologies
Personalized Cancer Vaccines
Test to Identify 18 Early-Stage Cancers
CAR T-Cell Therapy
Artificial Intelligence
Tablet to Cut Breast Cancer Risk
Nanoparticles
Pressurized Intraperitoneal Aerosol Chemotherapy
Cervical Cancer Treatment Breakthrough
New Developments
Biosimilar Approvals
Pipeline Analysis
Clinical Trial Analysis
Patent Analysis
Key Takeaways
Chapter 6 Supply Chain Analysis
Overview
Research and Development
Manufacturing
Packaging
Wholesale Distributors and Repackagers
Pharmacies
Dispensed to Consumers
Cancer Drug Shortage
Costs
Manufacturing Complexity
Geographic Concentration
Quality
Chapter 7 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis, by Cancer Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Liver Cancer
Cervix Cancer
Bladder Cancer
Kidney Cancer
Pancreatic Cancer
Ovarian Cancer
All Other Cancers
Geographic Breakdown
Market Analysis, by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 8 Competitive Intelligence
Overview
Blockbuster Oncology Pharmaceutical Brands
Global Market Shares of Leading Companies
Chapter 9 Sustainability in Cancers Therapeutics Market Emphasis on Recurrent and Metastatic Divisions: ESG Perspective
